Brokerages Expect Scpharmaceuticals Inc (SCPH) to Post ($0.50) Earnings Per Share

Scpharmaceuticals Inc (NASDAQ:SCPH) has been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price objective of $12.67 for the company and are expecting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also given Scpharmaceuticals an industry rank of 102 out of 255 based on the ratings given to related companies.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 21st. Jefferies Financial Group lowered their price objective on shares of Scpharmaceuticals from $26.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, June 14th. Leerink Swann lowered their price objective on shares of Scpharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, June 14th. Finally, BMO Capital Markets lowered their price objective on shares of Scpharmaceuticals from $24.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, June 14th.

Shares of SCPH stock traded up $0.20 during trading hours on Wednesday, hitting $5.62. 78,900 shares of the company were exchanged, compared to its average volume of 89,584. The company has a quick ratio of 13.80, a current ratio of 13.80 and a debt-to-equity ratio of 0.10. Scpharmaceuticals has a 52 week low of $4.10 and a 52 week high of $18.17. The company has a market capitalization of $97.49 million and a price-to-earnings ratio of -0.71.

Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.04. equities analysts expect that Scpharmaceuticals will post -2.09 EPS for the current year.

Hedge funds have recently modified their holdings of the company. Citigroup Inc. bought a new stake in shares of Scpharmaceuticals during the first quarter worth $481,000. Colony Group LLC bought a new position in Scpharmaceuticals in the second quarter valued at $131,000. Acadian Asset Management LLC bought a new position in Scpharmaceuticals in the second quarter valued at $169,000. BlackRock Inc. grew its position in Scpharmaceuticals by 21,048.8% in the first quarter. BlackRock Inc. now owns 288,469 shares of the company’s stock valued at $3,577,000 after purchasing an additional 287,105 shares in the last quarter. Finally, Northern Trust Corp bought a new position in Scpharmaceuticals in the first quarter valued at $595,000. 43.59% of the stock is owned by institutional investors.

About Scpharmaceuticals

scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.

Recommended Story: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply